You are viewing an incomplete version of our website. Please click to reload the website as full version.

CBL antibody (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence) (Tyr770)

Details for Product anti-CBL Antibody No. ABIN658935, Supplier: Log in to see
Antigen
  • 4732447J05Rik
  • C-CBL
  • c-Cbl
  • c-cbl-like
  • cbl
  • Cbl-2
  • CBL2
  • FRA11B
  • NSLL
  • RGD1561386
  • RNF55
Alternatives
anti-Human CBL antibody for Western Blotting
Epitope
Tyr770
47
41
27
24
18
5
4
4
4
3
3
3
3
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Human
255
143
136
6
4
4
4
1
1
1
Host
Mouse
206
37
17
1
Clonality
Monoclonal
Conjugate
This CBL antibody is un-conjugated
10
7
7
7
7
6
5
5
5
5
5
5
4
2
2
Application
Immunohistochemistry (IHC)
171
73
70
60
56
33
18
17
8
5
4
3
3
1
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Isotype IgG
Specificity The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Purification Affinity purified
Alternative Name C-Cbl (CBL Antibody Abstract)
Background The cbl oncogene was first identified as part of a transforming retrovirus which induces mouse pre-B and pro-B cell lymphomas. As an adaptor protein for receptor protein-tyrosine kinases, it positively regulates receptor protein-tyrosine kinase ubiquitination in a manner dependent upon its variant SH2 and RING finger domains. Ubiquitination of receptor protein-tyrosine kinases terminates signaling by marking active receptors for degradation.
Synonyms: RING finger protein 55, Casitas B-lineage lymphoma proto-oncogene, Proto-oncogene c-Cbl, Signal transduction protein CBL, E3 ubiquitin-protein ligase CBL
Molecular Weight 99633 DA
Gene ID 867
UniProt P22681
Research Area Signaling, Phospho-specific antibodies, Protein Modifications, Cancer, Cell Structure
Pathways TCR Signaling, Interferon-gamma Pathway, EGFR Signaling Pathway
Application Notes The suggested dilution is: IHC: 1:50-1:100
Comment

Background: The cbl oncogene was first identified as part of a transforming retrovirus which induces mouse pre-B and pro-B cell lymphomas. As an adaptor protein for receptor protein-tyrosine kinases, it positively regulates receptor protein-tyrosine kinase ubiquitination in a manner dependent upon its variant SH2 and RING finger domains. Ubiquitination of receptor protein-tyrosine kinases terminates signaling by marking active receptors for degradation.

Restrictions For Research Use only
Format Liquid
Concentration 1mg/ml
Buffer PBS, 0.02% sodium azide and 50% glycerol.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid freeze-thaw cycles.
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Expiry Date 6 months
Background publications Niemeyer, Kang, Shin, Furlan, Erlacher, Bunin, Bunda, Finklestein, Sakamoto, Gorr, Mehta, Schmid, Kropshofer, Corbacioglu, Lang, Klein, Schlegel, Heinzmann, Schneider, Starý, van den Heuvel-Eibrink et al.: "Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. ..." in: Nature genetics, Vol. 42, Issue 9, pp. 794-800, 2010 (PubMed).

Rocquain, Carbuccia, Trouplin, Raynaud, Murati, Nezri, Tadrist, Olschwang, Vey, Birnbaum, Gelsi-Boyer, Mozziconacci: "Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias." in: BMC cancer, Vol. 10, pp. 401, 2010 (PubMed).

Martinelli, De Luca, Stellacci, Rossi, Checquolo, Lepri, Caputo, Silvano, Buscherini, Consoli, Ferrara, Digilio, Cavaliere, van Hagen, Zampino, van der Burgt, Ferrero, Mazzanti, Screpanti, Yntema et al.: "Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. ..." in: American journal of human genetics, Vol. 87, Issue 2, pp. 250-7, 2010 (PubMed).

Matsuda, Taira, Sakashita, Saito, Tanaka-Yanagisawa, Yanagisawa, Nakazawa, Shiohara, Fukushima, Oda, Honda, Nakahata, Koike: "Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations." in: Blood, Vol. 115, Issue 26, pp. 5429-31, 2010 (PubMed).

Ye, Cihil, Stolz, Pilewski, Stanton, Swiatecka-Urban: "c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells." in: The Journal of biological chemistry, Vol. 285, Issue 35, pp. 27008-18, 2010 (PubMed).